Regeneron Pharmaceuticals Inc (REGN) Shares Sold by MUFG Securities EMEA plc

Share on StockTwits

MUFG Securities EMEA plc lessened its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 49.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,486 shares of the biopharmaceutical company’s stock after selling 5,266 shares during the period. MUFG Securities EMEA plc’s holdings in Regeneron Pharmaceuticals were worth $2,049,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the business. Robeco Institutional Asset Management B.V. grew its position in shares of Regeneron Pharmaceuticals by 21.9% in the third quarter. Robeco Institutional Asset Management B.V. now owns 5,564 shares of the biopharmaceutical company’s stock valued at $2,247,000 after purchasing an additional 1,000 shares during the last quarter. Victory Capital Management Inc. grew its position in shares of Regeneron Pharmaceuticals by 3.7% in the third quarter. Victory Capital Management Inc. now owns 8,785 shares of the biopharmaceutical company’s stock valued at $3,549,000 after purchasing an additional 315 shares during the last quarter. Janney Montgomery Scott LLC grew its position in shares of Regeneron Pharmaceuticals by 23.7% in the third quarter. Janney Montgomery Scott LLC now owns 5,616 shares of the biopharmaceutical company’s stock valued at $2,269,000 after purchasing an additional 1,075 shares during the last quarter. Dupont Capital Management Corp acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $390,000. Finally, Commonwealth Equity Services LLC grew its position in shares of Regeneron Pharmaceuticals by 22.9% in the third quarter. Commonwealth Equity Services LLC now owns 7,938 shares of the biopharmaceutical company’s stock valued at $3,207,000 after purchasing an additional 1,481 shares during the last quarter. 66.87% of the stock is currently owned by institutional investors.

Several research firms have recently commented on REGN. BidaskClub downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $441.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, February 6th. ValuEngine raised Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 15th. Zacks Investment Research downgraded Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 5th. Finally, BMO Capital Markets upped their target price on Regeneron Pharmaceuticals to $412.00 and gave the company a “market perform” rating in a research report on Thursday, February 7th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Regeneron Pharmaceuticals has an average rating of “Hold” and an average target price of $413.76.

In other Regeneron Pharmaceuticals news, VP Christopher R. Fenimore sold 1,848 shares of the firm’s stock in a transaction on Thursday, December 20th. The stock was sold at an average price of $358.97, for a total value of $663,376.56. Following the sale, the vice president now owns 9,871 shares of the company’s stock, valued at approximately $3,543,392.87. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Sanofi sold 131,115 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $412.17, for a total value of $54,041,669.55. The disclosure for this sale can be found here. Insiders have sold 134,754 shares of company stock worth $55,439,356 in the last three months. 12.42% of the stock is currently owned by company insiders.

Shares of NASDAQ:REGN opened at $414.47 on Friday. The company has a market cap of $45.29 billion, a P/E ratio of 20.93, a P/E/G ratio of 1.68 and a beta of 1.20. Regeneron Pharmaceuticals Inc has a 1 year low of $281.89 and a 1 year high of $442.00. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.67 and a current ratio of 4.47.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $5.10 by $1.74. The business had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.73 billion. Regeneron Pharmaceuticals had a return on equity of 29.77% and a net margin of 36.43%. The firm’s quarterly revenue was up 21.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.23 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.92 EPS for the current fiscal year.

WARNING: “Regeneron Pharmaceuticals Inc (REGN) Shares Sold by MUFG Securities EMEA plc” was reported by Week Herald and is the property of of Week Herald. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://weekherald.com/2019/03/17/regeneron-pharmaceuticals-inc-regn-shares-sold-by-mufg-securities-emea-plc.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: How to interpret a stock’s beta number

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply